Perceived barriers | Agree | Neutral | Disagree |
---|---|---|---|
Lack of convincing evidence regarding its effectiveness (N = 88) | 22% | 44% | 34% |
High sensitivity of drug -- drug interaction or drug allergy markers (N = 85) | 46% | 41% | 13% |
Concern about the degree of flexibility for the physician to override CDS-eP (N = 88) | 44% | 32% | 24% |
Lack of financial incentives (N = 87) | 70% | 24% | 6% |
Lack of acceptable, standardized product software (N = 88) | 61% | 33% | 7% |
Lack of a strategic plan for implementation (N = 89) | 78% | 20% | 2% |